Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Context Therapeutics Inc (NQ: CNTX )

0.6830 -0.0170 (-2.43%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 247,015
Open 0.7000
Bid (Size) 0.6812 (1)
Ask (Size) 0.6999 (5)
Prev. Close 0.7000
Today's Range 0.6739 - 0.7150
52wk Range 0.6000 - 2.790
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Context Therapeutics And 3 Other Stocks Under $1 Insiders Are Aggressively Buying
The Dow Jones closed higher by more than 250 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Myomo, Enzo Biochem And These 2 Stocks Under $2 Insiders Are Aggressively Buying
The Dow Jones closed lower by more than 600 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga

Performance

YTD
+1.32%
+1.32%
1 Month
+1.32%
+1.32%
3 Month
-45.79%
-45.79%
6 Month
-63.86%
-63.86%
1 Year
-66.52%
-66.52%

More News

Read More
Context Therapeutics and Lonza Enter Manufacturing Agreement for Bispecific Antibody Targeting Claudin 6-Positive Cancers
From Context Therapeutics Inc.
Via Globe NewsWire
Context Therapeutics® Highlights 2023 Corporate Priorities and Pipeline Milestones
From Context Therapeutics Inc.
Via Globe NewsWire
What About Women? This Company Targets Female-Focused Cancers
Via Benzinga
Why Express Shares Are Trading Higher By 39%? Here Are 50 Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Why Context Therapeutics Stock Is Falling 25% Today
Via Benzinga
Context Therapeutics® Reports Encouraging Preliminary Phase 2 Data for ONA-XR in Metastatic Breast Cancer
From Context Therapeutics Inc.
Via Globe NewsWire
Context Therapeutics® Nominates CTIM-76 Bispecific Antibody Candidate to Develop Treatment for Claudin 6-Positive Solid Tumors
From Context Therapeutics Inc.
Via Globe NewsWire
Context Therapeutics® Announces Clinical Updates on ONA-XR to be Presented at 2022 San Antonio Breast Cancer Symposium
From Context Therapeutics Inc.
Via Globe NewsWire
Context Therapeutics Partners With Integral Molecular To Develop An Emerging Cancer Drug
Via Benzinga
Context Therapeutics® Reports Third Quarter 2022 Operating and Financial Results
From Context Therapeutics Inc.
Via Globe NewsWire
New Ammo In The Battle Against Cancer – Context Therapeutics Sees Promising Results For Several Novel Drugs
Via Benzinga
69 Biggest Movers From Friday
Via Benzinga
40 Stocks Moving In Friday's Mid-Day Session
Via Benzinga
35 Stocks Moving In Monday's Mid-Day Session
Via Benzinga
66 Biggest Movers From Friday
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
68 Biggest Movers From Yesterday
Via Benzinga
26 Stocks Moving in Monday's Pre-Market Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 2, 2022
Via Benzinga
45 Biggest Movers From Yesterday
Via Benzinga
25 Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
32 Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.